Clinical Trial Update: Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2a clinical trial is investigating belantamab mafodotin for relapsed or refractory AL amyloidosis; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Amyloidosis

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: AL Amyloidosis, Amyloidosis | Phase 1, Phase 2 | Status: RECRUITING